Navigation Links
Personalized Treatments for Cancer Are Revolutionizing Patient Care
Date:6/15/2010

PORTLAND, Ore., June 15 /PRNewswire-USNewswire/ -- Raju Kucherlapati, Professor of Genetics at Harvard University—where he pioneered the use of genomic data in clinical decision making—will be addressing the Controlled Release Society on the subject of recent revolutionary advancements in personalized treatments for cancer patients.

"If you were diagnosed with non small cell lung cancer before 2003, there were not many treatment choices available to you," says Professor Kucherlapati. "If you are diagnosed with the same type of cancer today, it is most likely that the pathologist would order a series of genetic tests on the biopsy or surgically resected sample." The results of these tests would then be used to develop individually tailored approaches to patient treatment.

According to Professor Kucherlapati, the genetic tests performed on the tumor tissue would include the mutational status of EGFR, K-RAS, B-RAF, EML-ALK4 translocation, ErbB2 amplification, and perhaps others. Depending on the test results, a variety of treatments tailored to the specific type of tumor identified may be recommended by the oncologist.

For example, if the tumor being tested has certain types of EGFR mutations and does not have a K-RAS mutation, the oncologist may decide to treat the patient with a class of drugs called tyrosine kinase inhibitors.  If the tumor has ErbB2 amplification, the patient may be recommended to enroll in a clinical trial to evaluate the efficacy of Herceptin—a drug approved for treatment of certain breast cancer patients.  If the tumor has an EML-ALK4 translocation, the patient may be recommended to enter a different clinical trial for a drug being developed by Pfizer to treat patients with this particular type of tumor. 

Using these types of approaches, cancer treatments are being developed that are tailored to work best for each type of patient—not just for lung cancer, but for many solid tumors.  This type of personalized medicine is revolutionizing patient care. 

Raju Kucherlapati will deliver his speech, Genetics and Genomics in Clinical Medicine, at 8:00 AM on Monday, July 12, at the 37th Annual Meeting & Exposition of the Controlled Release Society (CRS), in the Oregon Convention Center, located in Portland, Oregon.

The Controlled Release Society (CRS) is an international society focused on the science and technologies for delivery of bioactive agents in pharmaceutical, non-pharmaceutical active ingredients, and in veterinary/animal-health related fields. The CRS Annual Meeting & Exposition is the internationally recognized conference for scientists and business development professionals in controlled release and delivery fields. For more information, please visit www.controlledrelease.org.

If you'd like more information about this topic, or to schedule an interview with Raju Kucherlapati, please contact Linda Schmitt at 651.994.3828 or email Linda at lschmitt@scisoc.org.


'/>"/>
SOURCE Controlled Release Society
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Arrowhead Releases New Report Assessing State of Personalized Medicine Market
2. HistoRx Receives Key Patent on Application of AQUA(R) Technology to Personalized Medicine
3. Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration
4. QuantaLife, Inc. Unanimously Selected as the Most Promising Company at the Personalized Medicine World Conference 2010
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference
7. Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine
8. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
9. Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders
10. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
11. Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... just published their findings on what they believe could be a new and ... of the new research. Click here to read it now. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):